Engitix Therapeutics announced it has closed a $25 million Series A extension financing led by Netherton Investments, a fund investing on behalf of Mike Platt, co-founder and managing director of BlueCrest Capital Management.
The company said proceeds will support continued preclinical development of its extracellular matrix (ECM)-targeted therapeutics pipeline across solid tumors and fibrosis, and further expansion of its platform built on what it describes as one of the largest proprietary ECM datasets spanning those disease areas. Engitix said it uses high-resolution ECM data to identify disease-associated signatures and translate them into therapeutics designed to act within diseased tissue microenvironments.
Engitix said it is developing therapies that target the ECM to treat cancer and fibrosis and noted existing strategic and collaboration relationships, including a drug discovery partnership with Dompé farmaceutici and development collaborations with Takeda in advanced fibrotic liver diseases.
KEY QUOTES:
“Closing this financing strengthens our ability to translate Engitix’s unique ECM understanding into a growing pipeline of targeted therapeutics. Our platform and dataset position us to accelerate preclinical development across oncology and fibrosis programs and build differentiated, ECM-targeted therapeutics with the potential to meaningfully improve patient outcomes.”
Giuseppe Mazza, CEO and Co-Founder, Engitix
“Engitix has developed a compelling strategy at the intersection of data, biology, and drug development. I’m pleased to continue supporting Engitix as it advances its programs in fibrosis and solid tumors.”
Mike Platt, Investor Director
